Effectiveness and acceptability of progestogens in combined oral contraceptives – a systematic review

[1]  R. Edgren,et al.  Totally synthetic (±)-13-Alkyl-3-hydroxy and methoxy-gona-1,3,5(10)-trien-17-ones and related compounds , 1963, Experientia.

[2]  C. Gerlinger,et al.  Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone , 2001 .

[3]  J. Foidart,et al.  A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[4]  J. Foidart,et al.  Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[5]  D. Mishell,et al.  Progestins and Antiprogestins in Clinical Practice , 1999 .

[6]  C. Gerlinger,et al.  Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. , 1999, Contraception.

[7]  I. Thorneycroft.  Cycle control with oral contraceptives: A review of the literature. , 1999, American journal of obstetrics and gynecology.

[8]  A. Di Lieto,et al.  Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 μg ethinyl estradiol combined with 150 μg desogestrel or 75 μg gestodene , 1999 .

[9]  Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg. , 1999, European journal of contraception & reproductive health care.

[10]  D. Serfaty,et al.  A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. , 1998, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[11]  M. Rosenberg,et al.  Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. , 1998, American journal of obstetrics and gynecology.

[12]  L. Bahamondes,et al.  Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. , 1998, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[13]  W. Rossmanith,et al.  [Comparative study on ovarian activity cycle stability and tolerance during administration of two low-dose oral contraceptives] , 1997 .

[14]  W. Ledger,et al.  A triphasic oral contraceptive pill, CTR-05: clinical efficacy and safety. , 1996, European journal of contraception & reproductive health care.

[15]  S. Koetsawang,et al.  Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. , 1995, Contraception.

[16]  D. Shoupe.  Multicenter Randomized Comparative Trial of Two Low‐Dose Triphasic Combined Oral Contraceptives Containing Desogestrel or Norethindrone , 1994, Obstetrics and Gynecology.

[17]  Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinyl estradiol and desogestrel/ethinyl estradiol. Latin American Oral Contraceptive Study Group. , 1994, Contraception.

[18]  C. Nappi,et al.  Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol. , 1993, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[19]  Ann E. Taylor.  A Clinical Guide for Contraception , 1993 .

[20]  F. Weber-Diehl,et al.  Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial. , 1993, Contraception.

[21]  R. Mukherjee,et al.  A comparative study of two low-dose combined oral contraceptives: results from a multicenter trial. , 1993, Contraception.

[22]  A. Decherney,et al.  EVALUATION OF A NEW GENERATION OF ORAL CONTRACEPTIVES , 1993, Obstetrics and gynecology.

[23]  P. Hillard.  Oral contraception noncompliance: The extent of the problem , 1992, Advances in contraception : the official journal of the Society for the Advancement of Contraception.

[24]  R. Percival-Smith,et al.  Cycle control on low-dose oral contraceptives: a comparative trial. , 1990, Contraception.

[25]  Reiter Sl,et al.  Initial selection of oral contraceptives. , 1990 .

[26]  N. Loudon,et al.  A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30. , 1990, European journal of obstetrics, gynecology, and reproductive biology.

[27]  L. Baer,et al.  Initial selection of oral contraceptives. , 1990, Journal of reproductive medicine.

[28]  W. Droegemueller,et al.  Triphasic Randomized Clinical Trial: comparative frequency of intermenstrual bleeding. , 1989, American journal of obstetrics and gynecology.

[29]  T. Osteria,et al.  A comparative analysis of three different dose combinations of oral contraceptives. , 1989, Contraception.

[30]  M. Kohlmeier,et al.  Clinical and metabolic effects of gestodene and levonorgestrel. , 1987, International journal of fertility.

[31]  N. Kase.  Hormonal Contraception , 1970, The Yale Journal of Biology and Medicine.

[32]  J. Siddall,et al.  Totally synthetic plus or minus-13-alkyl-3-hydroxy and methoxy-gona-135 (10)-trien-17-ones and related compounds. , 1963 .